Follow-up Messaging for Cancer

AH
KA
Overseen ByKathryn Anderson, MA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Texas Southwestern Medical Center
Must be taking: Chemotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health.

Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends.

After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.

Who Is on the Research Team?

AH

Arthur Hong, MD, MPH

Principal Investigator

University of Texas Southwestern Medical Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I currently have an active cancer diagnosis.
I am currently receiving chemotherapy.
* ED Arrival within 30 days of chemotherapy treatment
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Randomization and Intervention

Patients are randomized into control or intervention arms. Intervention arm receives structured follow-up messages via MyChart and text messaging within 24, 48, and 72 hours post-discharge.

3 days per discharge event
No in-person visits required

Outcome Tracking

Patients are monitored for time to next cancer treatment-related ED visit and engagement with OAC services. Follow-up occurs in 3-month intervals.

2 years maximum

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months intervals

What Are the Treatments Tested in This Trial?

Interventions

  • Follow-up messaging

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention
Group II: Control Arm (Usual Care)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Texas Southwestern Medical Center

Lead Sponsor

Trials
1,102
Recruited
1,077,000+